India, Nov. 20 -- CytoSorbents Corp. (CTSO), a medical device company specializing in blood purification technologies, Friday announced a $6.25 million stock financing and an agreement with Avenue Capital Group to reduce debt and extend its loan maturity.
Under the registered direct offering, the company will sell 556,681 shares at $4.94 each and 96,527 shares to directors and certain executives at $5.18 per share. It will also issue pre-funded warrants for up to 151,822 shares at $4.939 each.
CytoSorbents expects to receive about $4 million in gross proceeds. It plans to use the proceeds to repay $3 million of loan principal to Avenue, along with related fees, and for general corporate and working capital needs.
Separately, the company ...